Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PBH SEC filings page on Stock Titan provides access to regulatory documents for Prestige Consumer Healthcare Inc., a New York Stock Exchange–listed consumer healthcare products company. These filings offer detailed information on the company’s financial condition, operations and material events related to its over-the-counter (OTC) healthcare brands.
Prestige’s periodic reports, such as its annual and quarterly filings, describe performance in its North American OTC Healthcare and International OTC Healthcare segments, along with discussions of revenues, operating income, net income, earnings per share, free cash flow and leverage. They also provide context on category trends across gastrointestinal, women’s health, cough and cold, eye and ear care and other consumer health areas, as well as the role of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
Current reports on Form 8-K, several of which are referenced in the provided data, disclose events such as the release of quarterly earnings, the use of investor presentations and the entry into a material definitive agreement to acquire Pillar5 Pharma Inc., a Canadian sterile ophthalmic manufacturer and current Clear Eyes® supplier. These filings outline key terms of the transaction, closing conditions and related risk considerations.
On Stock Titan, users can view Prestige Consumer Healthcare’s filings as they are made available through EDGAR and use AI-powered summaries to interpret complex sections. This includes understanding how management presents non-GAAP measures like adjusted net income and adjusted diluted earnings per share, as well as reviewing risk factor discussions, segment information and material agreements that shape the company’s OTC healthcare business.
An affiliate of PBH has filed a Rule 144 notice to sell 281 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $16,860.00. The filing shows that 48,084,010 shares of this class were outstanding at the time of the notice, providing a baseline for the issuer’s equity size.
The shares to be sold were originally acquired on 05/04/2023 through restricted stock vesting from the issuer as compensation, rather than a cash purchase. The seller, Jeffrey A. Zerillo, also sold 719 shares of common stock on 11/28/2025 for $43,140.00 during the prior three months, as disclosed in the same notice.
PBH has a holder planning to sell 719 shares of its common stock under Rule 144. The planned sale is through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/28/2025 and an aggregate market value of 43140.00.
The securities being sold were acquired through restricted stock vesting from the issuer on 05/02/2025 and 05/05/2025, in amounts of 673 and 46 shares as compensation. As context, the number of shares of PBH common stock outstanding is reported as 48084010.
Prestige Consumer Healthcare Inc. (PBH) director John E. Byom reported a sale of company stock. On 11/25/2025, he sold 3,000 shares of common stock at a price of $59.35 per share in a single reported transaction where multiple lots at the same price were combined. After this sale, he beneficially owns 51,594 shares, held directly. The filing is made on Form 4, which reports changes in the ownership of company equity by an insider who serves as a director.
PBH has a Form 144 filing indicating a planned sale of common stock by a shareholder. The notice covers up to 3,000 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $178,050.00. The filing notes that 48,084,010 shares of the issuer’s stock are outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer as compensation: 2,295 shares vested on 08/01/2024 and 705 shares vested on 08/06/2025. The approximate date of the planned sale is 11/25/2025. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Ariel Investments, LLC filed a Schedule 13G reporting beneficial ownership of 3,594,959 shares of Prestige Consumer Healthcare (PBH) common stock, representing 7.3% of the class as of 09/30/2025.
The firm reports sole voting power over 3,214,409 shares and sole dispositive power over 3,594,959 shares, with no shared voting or dispositive power. Ariel states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Ariel’s adviser clients have the right to receive dividends or sale proceeds from the reported securities, and none of the clients holds an economic interest exceeding 5% of PBH’s outstanding common stock.
Prestige Consumer Healthcare (PBH) reported Q2 results. Total revenues were $274.1 million for the three months ended September 30, 2025, down 3.4% year over year. Net income was $42.2 million and diluted EPS was $0.86. Gross margin was 55.3%, slightly lower than 55.5% a year ago as International margins softened. Operating income was $79.7 million, while the effective tax rate rose to 38.9% primarily due to a new state tax presence.
For the six months, revenues were $523.6 million (down 5.0%) and operating cash flow reached $136.5 million. The company repurchased $109.8 million of stock at an average price of $70.34, ending with $119.1 million in cash. Long‑term debt remained $1.0 billion, with $190.0 million of unused capacity on the 2012 ABL Revolver. North American sales declined on Eye & Ear Care shortages, while Gastrointestinal grew; International revenue was roughly flat with mixed category performance.
Prestige Consumer Healthcare (PBH) announced financial results for the fiscal quarter and six months ended September 30, 2025. The company furnished a press release detailing the results as Exhibit 99.1 and an investor presentation as Exhibit 99.2.
Management began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026. The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, and are not subject to Section 18 liabilities unless specifically stated otherwise.
Schedule 13G/A disclosure by Ariel Investments, LLC reports beneficial ownership of 2,202,327 shares of Prestige Consumer Healthcare common stock, representing 4.5% of the class. Ariel states it has sole voting power over 1,950,287 shares and sole dispositive power over 2,202,327 shares. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Ariel notes its adviser clients have rights to dividends or sale proceeds on these securities and that no client has an economic interest exceeding 5%.